Skip to main content

Table 5 Conductance catheter derived parameters of left ventricular function in animals subjected to acute pulmonary hypertension

From: Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension

Parameter

Treatment

Baseline

Pulmonary hypertension

   

Pre-inhalation

5 minutes after inhalation

Mw (mWatt·s/ml)

Iloprost

8.29 ± 1.66

10.67 ± 2.45*

8.08 ± 2.22

 

Control

7.54 ± 1.06

9.01 ± 1.27*

9.24 ± 2.69

Emax (mmHg/ml)

Iloprost

1.10 ± 0.46

1.51 ± 0.74

1.20 ± 0.66

 

Control

1.13 ± 0.62

1.29 ± 0.75

1.64 ± 0.95

LVEF (%)

Iloprost

61 ± 5

63 ± 12

59 ± 13

 

Control

57 ± 9

53 ± 7

50 ± 5

τ/RR (ms)

Iloprost

0.06 ± 0.02

0.08 ± 0.02

0.07 ± 0.01

 

Control

0.07 ± 0.01

0.07 ± 0.01

0.08 ± 0.02

β (ml-1)

Iloprost

0.11 ± 0.03

0.11 ± 0.06

0.04 ± 0.03*

 

Control

0.11 ± 0.04

0.13 ± 0.09

0.09 ± 0.05

C (ml/mmHg)

Iloprost

0.72 ± 0.23

0.60 ± 0.20

0.64 ± 0.27

 

Control

0.88 ± 0.27

0.71 ± 0.25*

0.66 ± 0.21*

Ea (mmHg/ml)

Iloprost

1.87 ± 0.51

1.68 ± 0.44

1.67 ± 0.50

 

Control

1.80 ± 0.46

1.93 ± 0.55

1.95 ± 0.56

Emax/Ea

Iloprost

0.60 ± 0.24

0.92 ± 0.50

0.69 ± 0.30

 

Control

0.62 ± 0.24

0.67 ± 0.31

0.86 ± 0.48

  1. Values are shown for baseline and in pulmonary hypertension before inhalation and 5 minutes after inhalation of either iloprost or control. For the complete experimental time course, see Additional file 6. Values are expressed as mean ± standard deviation. *P < 0.05 versus baseline. β, chamber stiffness constant of end-diastolic pressure volume relationship; C, aortic compliance; Ea, effective arterial elastance; Emax, slope of the end-systolic pressure-volume relationship; LVEF, left ventricular ejection fraction; Mw, slope of the preload-recruitable stroke work relationship; τ/RR, time constant of ventricular relaxation, corrected for the RR interval.